Seeking Alpha

Based on a long view of profit potential, a number of drug stocks trade at lower valuations than...

Based on a long view of profit potential, a number of drug stocks trade at lower valuations than peers, SmartMoney says. After weeding out firms facing major patent issues in coming years, six winners should emerge: Glaxo (GSK +0.4%), Roche (RHHBY.PK -0.9%), Pfizer (PFE -1.9%), Sanofi (SNY -0.7%), Merck (MRK +0.8%), Novartis (NVS +0.3%).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)